MTMR3 risk allele enhances innate receptor-induced signaling and cytokines by decreasing autophagy and increasing caspase-1 activation

Amit Lahiri, Matija Hedl, and Clara Abraham†

Department of Medicine, Yale University, New Haven, CT 06511

Edited by David Artis, Weill Cornell Medical College, New York, NY, and accepted by the Editorial Board July 10, 2015 (received for review January 27, 2015)

Inflammatory bowel disease (IBD) is characterized by dysregulated host-microbial interactions and cytokine production. Host pattern recognition receptors (PRRs) are critical in regulating these interactions. Multiple genetic loci are associated with IBD, but altered functions for most, including in the rs713875 MTMR3/HORMAD2/LIF/OSM region, are unknown. We identified a previously undefined role for myotubularin-related protein 3 (MTMR3) in amplifying PRR-induced cytokine secretion in human macrophages and defined MTMR3-initiated mechanisms contributing to this amplification. MTMR3 decreased PRR-induced phosphatidylinositol 3-phosphate (PtdIns3P) and autophagy levels, thereby increasing PRR-induced caspase-1 activation, autocrine IL-1β secretion, NFκB signaling, and, ultimately, overall cytokine secretion. This MTMR3-mediated regulation required the N-terminal pleckstrin homology-GRAM domain and Cys413 within the phosphatase domain of MTMR3. In MTMR3-deficient macrophages, reducing the enhanced autophagy or restoring NFκB signaling rescued PRR-induced cytokines. Macrophages from rs713875 CC IBD risk carriers demonstrated increased MTMR3 expression and, in turn, decreased PRR-induced PtdIns3P and autophagy and increased PRR-induced caspase-1 activation, signaling, and cytokine secretion. Thus, the rs713875 IBD risk polymorphism increases MTMR3 expression, which modulates PRR-induced outcomes, ultimately leading to enhanced PRR-induced cytokines.

The authors declare no conflict of interest.

Significance
This study describes a previously undefined role for myotubularin-related protein 3 (MTMR3) in modulating pattern recognition receptor (PRR)-induced responses and identifies mechanisms mediating these outcomes in primary human macrophages. It further defines that MTMR3 in the inflammatory bowel disease risk MTMR3/HORMAD2/LIF/OSM locus accounts for the genotype-dependent regulation of PRR-initiated outcomes in macrophages. Our studies highlight mechanisms whereby MTMR3 may contribute to intestinal inflammation, specifically both by inhibiting autophagy and by enhancing signaling and cytokine secretion upon stimulation of a broad range of PRRs.


Supporting Information online
Results

**Human Myeloid-Derived Cells from IBD Risk-Associated rs713875 CC Carriers Demonstrate Increased PRR-Induced Cytokine Secretion.** PRR-initiated outcomes, including cytokine secretion, in myeloid-derived cells are important in IBD pathophysiology (9). As the rs713875 MTMR3/HORMAD2/LIF/OSM region polymorphism is associated with IBD (3) contains genes with roles in autophagy [e.g., MTMR3 (5–7)], which can indirectly modulate cytokine secretion, and genes regulating T-cell cytokines [e.g., LIF, OSM], we questioned if this polymorphism modulates PRR-initiated cytokines. The PRR nucleotide-binding oligomerization domain 2 (NOD2) is associated to Crohn’s disease (1). We therefore used muramyl dipeptide (MDP), the peptidoglycan component that specifically activates NOD2, to treat MDMs from 100 healthy individuals. We examined IL-1β protein secretion, given its role in amplifying cytokines in MDMs (11). IL-1β secretion was normalized to untreated cells, and data were log2 transformed. MDMs from rs713875 C risk genotype carriers secreted increased IL-1β upon NOD2 stimulation compared with GG carriers (Fig. L4). Effects were most pronounced at low MDP doses, but persisted at higher doses (Fig. L4). Similar results were observed with tumor necrosis factor (TNFα) secretion (Fig. S1A).

Both the NOD2 ligand peptidoglycan and the TLR2 ligand lipotechoic acid are present in Gram-positive bacteria. MDMS treated with PamCys, a synthetic TLR2 ligand, also showed increased IL-1β (Fig. LB) and TNFα (Fig. S1B) protein secretion. Cytokine secretion from NOD2- and TLR2-stimulated MDMs (Fig. 1A and B) and monocyte-derived dendritic cells (MDDCs) (Fig. 1C) was similarly regulated by rs713875 genotype. In the intestine, additional PRRs are activated by microbial products. In MDDCs from a separate cohort of 98 healthy individuals, rs713875 C carriers secreted increased IL-1β (Fig. 1C) and TNFα (Fig. S1C).

**MTMR3 Is Required for Optimal PRR-Induced Cytokine Secretion.** We next questioned which gene(s) in the MTMR3/HORMAD2/LIF/OSM region accounts for the genotype-dependent regulation of PRR-induced cytokine secretion observed. HORMAD2 regulates cell cycle progression, and its expression has not been described in myeloid cells. We did not detect HORMAD2 mRNA in primary human MDMs; as expected, it was expressed in HepG2 liver cells (Fig. S24). We then used siRNA to effectively knock down the expression of LIF, OSM (Fig. S2B), and MTMR3 (Fig. S2C). Leukemia inhibitory factor (LIF) and Oncostatin M (OSM) knockdown did not affect PRR-induced cytokine secretion (Fig. S2D). We confirmed the lack of a role for LIF and OSM in regulating PRR-induced cytokine secretion through an independent approach using LIF receptor and OSM blocking antibodies (Fig. S2E). The antibodies were functional, as they effectively decreased IFNγ secretion from stimulated Jurkat T cells (Fig. S2F). In contrast, MTMR3 knockdown decreased NOD2-induced pro- and anti-inflammatory cytokines (Fig. 2A). Cell viability was intact (Fig. S3A), and cells remained responsive to an alternative pathway through dectin stimulation (Fig. S3B). We confirmed Fig. 24 results with three additional siRNA constructs to MTMR3 (Fig. S3 C and D). Moreover, we considered additional gene candidates somewhat further from rs713875, including NF2, CABP7, and ZMAT5. Effective knockdown of these genes (Fig. S2G) did not alter NOD2-induced cytokine secretion in human MDMs (Fig. S2D). Finally, consistent with the rs713875 genotype regulation of cytokines upon stimulation of various PRRs (Fig. 1C and Fig. S1C), MTMR3 knockdown in MDMs decreased cytokine secretion upon stimulation of multiple PRRs (Fig. S3E).

**IBD Risk rs713875 C Carriers Express Higher Levels of MTMR3.** Given the ability of MTMR3 to regulate PRR-induced cytokines and the location of the rs713875 polymorphism in a region ~165 kb from MTMR3, we hypothesized the polymorphism would lead to altered MTMR3 expression. Rs713875 C risk carriers demonstrated increased MTMR3 mRNA (Fig. 2B) and protein (Fig. 2C) expression relative to GG individuals. As reducing MTMR3 expression through siRNA decreased PRR-induced cytokines (Fig. 2A), the increased MTMR3 expression in rs713875 C risk carriers is consistent with the increased PRR-induced cytokines observed in these cells. Of note, the rs713875 genotype did not regulate following TLR2, TLR3, TLR4, TLR5, TLR7, and TLR9 stimulation. Taken together, myeloid cells from rs713875 IBD risk carriers in the MTMR3/HORMAD2/LIF/OSM region show increased PRR-induced cytokine secretion.
the expression of two other genes in the region, LIF or OSM (Fig. S2H). Taken together, the rs713875 risk genotype increases MTMR3 mRNA and protein expression, and MTMR3 increases PRR-induced cytokine secretion, thereby implicating MTMR3 in the regulation of PRR-induced cytokines in myeloid-derived cells from rs713875 carriers.

MTMR3 Is Required for Optimal PRR-Induced Nfkβ and P13K Activation. NOD2 stimulation activates the MAPK, Nfkβ, and P13K pathways (11–15), and these pathways lead to cytokine secretion (15, 16). We therefore asked if these pathways were modulated by MTMR3. As expected, ERK, p38, and JNK were activated upon NOD2 stimulation (Fig. S4A). However, MTMR3 knockdown did not alter their activation (Fig. S4A). In contrast, MTMR3 knockdown significantly decreased NOD2-induced activation of the Nfkβ (Fig. S4B) and P13K (Fig. S4C) pathways.

MTMR3 Inhibits PRR-Induced Autophagy. We next questioned the mechanisms through which MTMR3 regulates PRR-induced signaling and cytokines. MTMR3 has not been previously implicated in regulating cytokine secretion in general, and PRR-induced cytokine secretion in particular. MTMR3 inhibits constitutive autophagy in select cell lines (5–7). Autophagy can inhibit inflammasome activation, thereby decreasing IL-1β secretion (17–19). Whereas IL-1β can contribute to both apoptotic and nonapoptotic cell death (20), autocrine IL-1β secretion can also dramatically amplify PRR-induced secretion of additional cytokines in human MDMs (11, 15). Prior studies identified that NOD2 stimulation can contribute to autophagy (21–23). We therefore hypothesized that MTMR3 would regulate NOD2-induced autophagy. As expected, NOD2 stimulation induced autophagy in MDMs as assessed by LC3II up-regulation by Western blot (Fig. 3A); we previously ensured that NOD2-induced LC3II expression was due to increased autophagic flux (24). Upon MTMR3 knockdown, the baseline low level of LC3II expression was not altered, but NOD2-induced autophagy was increased relative to scrambled siRNA-transfected cells (Fig. 3A). We confirmed these results through an independent microscopic approach examining LC3 punctae (Fig. 3B and Fig. S3A for higher magnification). Therefore, MTMR3 inhibits NOD2-induced autophagy in human MDMs.

We next questioned if the MTMR3-mediated regulation of NOD2-induced autophagy, in turn, regulates NOD2-induced cytokine secretion. We therefore inhibited the enhanced autophagy observed upon NOD2 stimulation in MTMR3-deficient cells through two independent approaches, pharmacological inhibition using 3-methyl adenine (3-MA) and siRNA to two separate autophagy-associated proteins, the Crohn’s disease-associated ATG16L1 (3) and ATG5. We confirmed that ATG16L1 (Fig. S5B) and ATG5 (Fig. S5D) knockdown resulted in decreased NOD2-induced autophagy (Fig. S5C and E). Reducing autophagy through each of these approaches rescued NOD2-induced cytokines in MTMR3-deficient MDMs (Fig. 3C and Fig. S5F). Therefore, MTMR3 decreases NOD2-induced autophagy, which in turn increases NOD2-induced cytokine secretion.

Upon NOD2 stimulation, MTMR3 Relocalizes to the Nucleus, and PtdIns3P Levels Increase. We next questioned how MTMR3 expression and localization is regulated during NOD2 stimulation in MDMs. Neither MTMR3 mRNA (Fig. S5G) nor protein (Fig. S5H) expression was altered upon NOD2 stimulation. Previous reports examining MTMR3 overexpression found MTMR3 distributed in the cytoplasm and reticular network in HeLa cells (5, 7). Given that MTMR3 inhibits autophagy, and yet autophagy increases with NOD2 stimulation, we hypothesized that MTMR3 might undergo cellular redistribution upon NOD2 stimulation. Endogenous MTMR3 was distributed predominantly in the cytoplasm of unstimulated human MDMs (Fig. 3D). However, upon NOD2 stimulation, MTMR3 transiently redistributed to the nucleus, with redistribution peaking 2 h after stimulation (Fig. 3D). Interestingly, Alfy, which enhances autophagy, demonstrates a reverse nuclear to autophagic membrane translocation (25). MTMR3 has been reported to dephosphorylate PtdIns3P; thereby reducing

Fig. 3. MTMR3 inhibits NOD2-induced autophagy. (A and B) MDMs were transfected with scrambled or MTMR3 siRNA for 48 h and then treated with 100 μg/mL MDP for 6 h. (A) Representative Western blot of LC3II expression and summarized densitometry of fold LC3II induction normalized to untreated, scrambled siRNA-transfected cells (represented by the dotted line at 1) ± SEM (n = 10). (B) Cells were immunostained for LC3II (red) and nucleus (DAPI; blue). Representative image and summarized data (n = 6; 10 fields per donor), shown as the percent of LC3 puncta-positive cells ± SEM. (Scale bar, 10 μm.) (C) MDMs (n = 4) were transfected with MTMR3 siRNA ± transfected with scrambled or ATG16L1 siRNA for 48 h or ± treated with 10 mM 3-MA for 1 h and then treated with 100 μg/mL MDP for 24 h. Cytokine secretion ± SEM. Similar results were observed for an additional n = 6. (D) MDMs were treated with 100 μg/mL MDP for the indicated times. MTMR3 expression in the cytoplasm and nucleus by Western blot. Summarized data for MTMR3 expression normalized to the loading controls ± SEM (n = 6). Loading controls included GAPDH for cytoplasm and TBP for nucleus. (E) MDMs (n = 4) were transfected with scrambled or MTMR3 siRNA for 48 h, then treated with 100 μg/mL MDP for 2 h. PtdIns3P levels ± SEM. Similar results were observed in an additional n = 4. Sc, scrambled; Tx, treatment. *P < 0.05; **P < 0.01; ***P < 0.001.
cellular PtdIns3P levels (4, 5). Local PtdIns3P levels are associated with autophagy initiation and maturation (26, 27). We therefore asked if NOD2-induced PtdIns3P levels were regulated in accordance with MTMR3 relocalization. PtdIns3P levels increased 2 h after NOD2 stimulation (Fig. S3E), consistent with the decreased cytoplasmic MTMR3 (Fig. 3D). Moreover, both baseline and NOD2-stimulated PtdIns3P levels were higher in MTMR3 knockdown relative to control knockdown macrophages (Fig. 3E). The degree of PtdIns3P modulation is consistent with that observed with the myotubulbin MTMR1 (28). TLR4 and TLR9 stimulation also led to MTMR3 nuclear localization (Fig. S6A), and MTMR3-dependent attenuation of PtdIns3P (Fig. S6B) and autophagy (Fig. S6C). Taken together, MTMR3 regulates PtdIns3P levels, with the PRR-mediated increase of cytoplasmic PtdIns3P levels associated with a transient redistribution of MTMR3 from the cytoplasm to the nucleus, such that this redistribution may serve as a mechanism for regulating PtdIns3P and autophagy levels.

MTMR3 Is Required Both for Optimal NOD2-Induced Caspase-1 Activation and Early Autocrine IL-1β Secretion and for IL-1R-Induced Signaling. Autophagy can inversely regulate inflammasome activation (17–19); inflammasome activation, in turn, results in production of mature IL-1β, which is critical for NOD2-induced secretion of a broad range of cytokines (11, 15) (Fig. S7A). Therefore, we questioned if MTMR3 increases NOD2-induced caspase-1 activation. Upon MTMR3 knockdown in MDMs, NOD2-induced caspase-1 activation (Fig. 4A and Fig. S7B) and early IL-1β secretion (within 15 min) (Fig. 4B) was decreased; this early IL-1β secretion is caspase-1-dependent and transcriptionally independent (11, 29). Furthermore, consistent with IL-1R signaling through the IRAK-1-TRAF6 pathway common to PRRs and with MTMR3 regulation of cytokine induction upon stimulation of various PRRs (Fig. 1 and Fig. S3E), MTMR3 was required for optimal IL-1R-induced signaling (Fig. S7C) and cytokine secretion (Fig. 4C). Therefore, MTMR3 is required both for optimal NOD2-induced caspase-1 activation and early autocrine IL-1β secretion and for IL-1R–mediated responses to this autocrine IL-1β. Consistent with the requirement for MTMR3 in optimal IL-1R-induced signaling, supplementing NOD2-stimulated MTMR3-deficient MDMs with IL-1β was unable to fully restore cytokines (Fig. 7D). As NOD2-induced autocrine IL-1β was required for optimal NFκB activation (Fig. 4D) and MTMR3 was required for optimal NOD2-induced NFκB activation (Fig. S4B), we questioned if restoring NFκB activation in MTMR3-deficient MDMs (Fig. S7E) could restore NOD2-induced cytokines. We found this to be the case (Fig. 4E). Therefore, MTMR3 both increases NOD2-induced caspase-1 activation, which increases autocrine IL-1β secretion, and directly regulates IL-1R signaling; these combined effects increase NFκB signaling and amplify the secretion of additional cytokines.

MTMR3 Modulation of PRR Outcomes Requires the PH-GRAM Domain and Catalytic C413 in the Phosphatase Domain of MTMR3. We next sought to define structural requirements in MTMR3 for its regulation of PRR-induced outcomes. The N-terminal PH-GRAM domain (which can mediate binding to PtdIns3P) and the catalytic-regulating Cys413 within the phosphatase domain of MTMR3 are required for catalytic activity toward the PtdIns3P substrate and for inhibiting constitutive autophagy in cell lines (5, 7). To determine if these sites were required for regulating PtdIns3P levels and autophagy upon PRR stimulation in MDMs, we generated MTMR3 mutants with a PH-GRAM domain deletion (deletion amino acids 1–119) and a Cys413 replacement with serine (Fig. S8A). The three MTMR3 variants overexpressed to equivalent levels in MDMs (~fourfold over endogenous MTMR3) (Fig. S8B); as expected, the PH-GRAM deletion showed a lower expressing band in addition to endogenous MTMR3 (Fig. S8B). WT MTMR3 overexpression in MDMs reduced NOD2-induced PtdIns3P levels (Fig. S4A) and autophagy (Fig. S5B), and increased NOD2-induced caspase-1 activation (Fig. 5C) and cytokine secretion (Fig. 5D). In contrast, the PH-GRAM deletion and C413S MTMR3 variants were impaired in these outcomes (Fig. 5). Similar to endogenous MTMR3, each of the MTMR3 variants underwent nuclear localization upon NOD2 stimulation (Fig. S8C). Therefore, through complementary knockdown and overexpression approaches, we establish a clear role for MTMR3 in modulating NOD2-induced PtdIns3P levels and autophagy, caspase-1 activation, and subsequent autocrine IL-1β–initiated signaling, which in turn regulate secretion of additional cytokines. We further define that each of these outcomes is dependent upon the PH-GRAM domain and Cys413 within the phosphatase domain of MTMR3.

rs713875 risk C Allele in the MTMR3 Region Is Associated with Decreased NOD2-Induced PtdIns3P and Autophagy and Increased NOD2-Induced Caspase-1 Activation and Signaling. Given the increased MTMR3 expression (Fig. 2) and increased PRR-induced cytokines (Fig. 1) in rs713875 C individuals, we next examined signaling regulation in these risk carriers. As MTMR3 regulates NOD2-induced NFκB and PI3K activation (Fig. S4), we examined these pathways. MDMs from rs713875 CC risk carriers demonstrated increased NOD2-induced NFκB and PI3K pathway activation relative to CC risk carriers (Fig. 6A), whereas the expression of MDMs from these combined effects increase NFκB signaling and amplify the secretion of additional cytokines.

**Fig. 4.** MTMR3 is required both for optimal NOD2-induced caspase-1 activation and early autocrine IL-1β secretion and for IL-1R-induced signaling. (A) MDMs were transfected with scrambled or MTMR3 siRNA, then treated with 100 μg/mL MDP for 6 h. Representative Western blot for active caspase-1 p20 expression and summarized data for fold caspase-1 normalized to untreated, scrambled siRNA-transfected cells (represented by the dotted line at 1) + SEM (n = 8). (B) MDMs (n = 4) were transfected with scrambled or MTMR3 siRNA, then cotransfected with IL-1Ra (to block IL-1β consumption) and treated with 100 μg/mL MDP for 15 min. Early IL-1β secretion + SEM. (C) MDMs (n = 4) were transfected with scrambled or MTMR3 siRNA and then treated with 10 ng/mL IL-1β for 24 h. Cytokine secretion + SEM. (D) MDMs (n = 8) were pretreated with 0.5 μg/mL IL1Ra for 1 h and then treated with 100 μg/mL MDP for 15 min, and phospho-IRAK1 induction was assessed. Representative histogram with mean fluorescence intensity (MFI) values and summary of fold phospho-IRAK1 induction + SEM. (E) MDMs (n = 4) were transfected with scrambled or MTMR3 siRNA, along with empty vector or a vector expressing IKK-2 S177D S181E leading to constitutive NFκB activation (ca-NFκB) and then treated with 100 μg/mL MDP for 24 h. Cytokine secretion + SEM. Scr, scrambled; Tx, treatment. **P < 0.01; ***P < 0.001; *P < 1 × 10−4; †P < 1 × 10−5.
levels (Fig. 6). We now identify a distinct mechanism for decreasing PRR-induced autophagy through the IBD-associated gain-of-function of an autophagy inhibitor, MTMR3. Autophagy is able to both increase bacterial clearance and decrease PRR-induced cytokine secretion in macrophages, two cellular outcomes that are critical to intestinal immune homeostasis. Intestinal macrophages, which have increased levels of autophagy relative to peripheral macrophages (24), similarly demonstrate improved bacterial clearance, despite a dramatic reduction in PRR-induced cytokines (31), thereby highlighting the importance of the dual regulation of these cellular processes in intestinal macrophages. Therefore, the reduced autophagy in MTMR3 IBD risk individuals may confer risk through the regulation of multiple downstream outcomes. Moreover, as PtdIns3P levels can contribute to membrane trafficking and various signaling protein outcomes, there are likely other cellular processes modulated in individuals with MTMR3 polymorphisms that contribute to both PRR-dependent and PRR-independent outcomes.

We have identified that polymorphisms in the MTMR3 region regulate outcomes across a broad range of PRRs in MDMs from IBD risk carriers. It is possible that in addition to MTMR3, rs713875 may regulate other genes in the region in distinct cell subsets and/or in additional functional outcomes. Our findings define a critical role for MTMR3 in processes crucial for intestinal immune homeostasis, including the regulation of PRR-initiated outcomes in human macrophages, and identify that in

Moreover, upon NOD2 stimulation, cells from rs713875 CC risk carriers had reduced cellular PtdIns3P levels (Fig. 6D) and autophagy (Fig. 6C) and increased caspase-1 activation (Fig. 6D) relative to GG carriers, in accordance with the increased cytokines in rs713875 CC MDMs (Fig. 1). Of note, MTMR3 was able to localize to the nucleus after NOD2 stimulation in both CC and GG carriers, albeit MTMR3 nuclear levels in CC carriers were higher, in accordance with overall higher cellular levels (Fig. S9).

**Discussion**

In this study, we dissected a previously unidentified role for MTMR3 in PRR-induced outcomes and defined mechanisms through which the IBD-associated risk variant in the MTMR3 region modulates these outcomes. We found that MTMR3 increases PRR-induced signaling and cytokine secretion in human macrophages. We identified mechanisms for this PRR-mediated regulation; MTMR3 decreases PRR-induced PtdIns3P levels and autophagy, thereby increasing PRR-induced caspase-1 activation and autocrine IL-1β secretion, along with subsequent amplification of signaling and secretion of additional cytokines. The PH-GRAM domain and catalytic function of MTMR3 were required for these outcomes. Consistent with the roles that we define for MTMR3 in PRR-induced signaling, the enhanced MTMR3 expression in rs713875 IBD risk CC carriers is associated with decreased NOD2-induced cellular PtdIns3P levels and autophagy and increased PRR-induced caspase-1 activation, signaling, and cytokine secretion, thereby resulting in enhanced inflammatory outcomes (Fig. S10).

We have found that MTMR3 is required for both optimal NOD2-induced autocrine IL-1β secretion (through regulation of PRR-induced inflammasome activation) and optimal signaling through the IL-1R, highlighting multiple levels at which MTMR3 regulates PRR-induced cytokines. MTMR3 is also required for optimal signaling in response to TNFα, IL-12, and IFNγ treatment of MDMs (Fig. S10B), thereby implicating MTMR3 in modulating a range of cytokines and PRR ligands.

Loss-of-function IBD risk polymorphisms are observed in *IRGM* and *ATG16L1* (2, 3), which are positive regulators of autophagy. Mice generated to express the *ATG16L1* variant associated with Crohn’s disease demonstrate decreased autophagy and increased IL-1β production (30). We now identify a distinct mechanism for decreasing PRR-induced autophagy through the IBD-associated gain-of-function of an autophagy inhibitor, MTMR3. Autophagy is able to both increase bacterial clearance and decrease PRR-induced cytokine secretion in macrophages, two cellular outcomes that are critical to intestinal immune homeostasis. Intestinal macrophages, which have increased levels of autophagy relative to peripheral macrophages (24), similarly demonstrate improved bacterial clearance, despite a dramatic reduction in PRR-induced cytokines (31), thereby highlighting the importance of the dual regulation of these cellular processes in intestinal macrophages. Therefore, the reduced autophagy in MTMR3 IBD risk individuals may confer risk through the regulation of multiple downstream outcomes. Moreover, as PtdIns3P levels can contribute to membrane trafficking and various signaling protein outcomes, there are likely other cellular processes modulated in individuals with MTMR3 polymorphisms that contribute to both PRR-dependent and PRR-independent outcomes.

We have identified that polymorphisms in the MTMR3 region regulate outcomes across a broad range of PRRs in MDMs from IBD risk carriers. It is possible that in addition to MTMR3, rs713875 may regulate other genes in the region in distinct cell subsets and/or in additional functional outcomes. Our findings define a critical role for MTMR3 in processes crucial for intestinal immune homeostasis, including the regulation of PRR-initiated outcomes in human macrophages, and identify that in

**Discussion**

In this study, we dissected a previously unidentified role for MTMR3 in PRR-induced outcomes and defined mechanisms through which the IBD-associated risk variant in the MTMR3 region modulates these outcomes. We found that MTMR3 increases PRR-induced signaling and cytokine secretion in human macrophages. We identified mechanisms for this PRR-mediated regulation; MTMR3 decreases PRR-induced PtdIns3P levels and autophagy, thereby increasing PRR-induced caspase-1 activation and autocrine IL-1β secretion, along with subsequent amplification of signaling and secretion of additional cytokines. The PH-GRAM domain and catalytic function of MTMR3 were required for these outcomes. Consistent with the roles that we define for MTMR3 in PRR-induced signaling, the enhanced MTMR3 expression in rs713875 IBD risk CC carriers is associated with decreased NOD2-induced cellular PtdIns3P levels and autophagy and increased PRR-induced caspase-1 activation, signaling, and cytokine secretion, thereby resulting in enhanced inflammatory outcomes (Fig. S10).

We have found that MTMR3 is required for both optimal NOD2-induced autocrine IL-1β secretion (through regulation of PRR-induced inflammasome activation) and optimal signaling through the IL-1R, highlighting multiple levels at which MTMR3 regulates PRR-induced cytokines. MTMR3 is also required for optimal signaling in response to TNFα, IL-12, and IFNγ treatment of MDMs (Fig. S10B), thereby implicating MTMR3 in modulating a range of cytokines and PRR ligands.
Informed consent was obtained per institutional review board at Yale University. Recruited participants with no personal or family history of autoimmune/inflammatory disease, including psoriasis, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, type I diabetes mellitus, Crohn’s disease, and ulcerative colitis, or a history of HIV. Given the limitation in powered sample size, the range of innate responses we sought to examine, two separate cohorts of 100 and 98 individuals were recruited for NOF2/LIR2 d–s response studies in MDMs and PRR-induced cytokine studies in MDCDs, respectively. We performed genotyping by TaqMan (Applied Biosystems) or Sequenom platform (Sequenom, Inc.).

**Materials and Methods**

**Patient Recruitment and Genotyping.** Informed consent was obtained per institutional review board at Yale University. Recruited participants with no personal or family history of autoimmune/inflammatory disease, including psoriasis, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, type I diabetes mellitus, Crohn’s disease, and ulcerative colitis, or a history of HIV. Given the limitation in powered sample size, the range of innate responses we sought to examine, two separate cohorts of 100 and 98 individuals were recruited for NOF2/LIR2 d–s response studies in MDMs and PRR-induced cytokine studies in MDCDs, respectively. We performed genotyping by TaqMan (Applied Biosystems) or Sequenom platform (Sequenom, Inc.).

**Myeloid Cell Isolation and Cell Culture.** Monocytes were purified from human peripheral blood mononuclear cells by positive CD14 selection (Miltenyi Biotec) or adhesion, tested for purity, and cultured with 10 ng/mL M-CSF (Shenandoah Biotechnology) for MDMs or 40 ng/mL GM-CSF and 40 ng/mL IL-4 (R&D Systems, Inc.) for MDCDs, as in ref. 32. Cultured myeloid cells were treated with MDPA (Bachem), lipid A (Peptides International), polyI:C, IL-4 (R&D Systems, Inc.) (for MDDCs), or 40 ng/mL GM-CSF and 40 ng/mL Biotec) or adhesion, tested for purity, and cultured with 10 ng/mL M-CSF (Shenandoah Biotechnology) (for MDMs) or 20 ng/mL M-CSF (Life Technologies) (for MDCDs). In particular, our genotyping studies employed the human peripheral blood mononuclear cell (PBMC) panel (sourced from Anjana Rao, La Jolla Institute for Allergy & Immunology, La Jolla, CA [33]) or empty vector, were transfected into MDMs using nucleofector kit (Amaxa). The HA–MTMR3 C413S mutant was generated through site-directed mutagenesis (QuickChange Lightning Kit; Agilent Technologies), and the N-terminal PH-GARM deletion mutant was generated through PCR with deletion of the N-terminal 1–19 amino acids of WT HA–MTMR3 in pcDNA3.

**Transfection of siRNAs and DNA Vectors.** Pooled siRNA containing four different siRNAs for each MTMR3 and ATG16L1 (SMARTpool, Dharmacon), scrambled siRNA (Dharmacon), or 2 μg HA–MTMR3 (generous gift of Michael J. Clague, University of Liverpool, Liverpool, UK), which was then subcloned into pcDNA3.2, 2 μg IKK-2 S177D S181E [Addgene plasmid 11015; kindly deposited by Anjana Rao, La Jolla Institute for Allergy & Immunology, La Jolla, CA [33]] or empty vector, were transfected into MDMs using nucleofector kit (Amaxa). The HA–MTMR3 C413S mutant was generated through site-directed mutagenesis (QuickChange Lightning Kit; Agilent Technologies), and the N-terminal PH-GAM deletion mutant was generated through PCR with deletion of the N-terminal 1–19 amino acids of WT HA–MTMR3 in pcDNA3.

**Protein Expression Analysis.** Western blot was performed using anti-LC3 (Cell Signaling), anti–caspase-1 p20 (Santa Cruz), or anti–ATG16L1 (Abcam), and quantified using Alexa Fluor 647- or anti-rabbit IgG (Jackson Laboratories). Fluorescence microscopy was conducted with the Zeiss Axios Observer microscope (Carl Zeiss Microscopy).

**Microscopic Analysis.** MDMs were fixed in paraformaldehyde and then incubated with anti-LC3 (Cell Signaling), followed by Cy5-conjugated goat anti-rabbit IgG (Jackson Laboratories). Nuclei were stained with DAPI (Acros Organics). Fluorescence microscopy was conducted with the Zeiss Axios Observer microscope (Carl Zeiss Microscopy).

**PtdIns3P Measurement.** PtdIns3P levels were quantified using a PtdIns3P mass assay kit per manufacturer’s protocol (Echelon Biosciences).

**Statistical Analysis.** Significance was assessed using two-tailed Student t test. A Bonferroni correction was applied for multiple comparisons as appropriate. P < 0.05 was considered significant.

**ACKNOWLEDGMENTS.** We thank Dr. Michael J. Clague for reagents. This work was supported by The Broad Foundation, the National Institutes of Health (DK099907, DK077905, DK062422, DK-P30-34989), and the Crohn’s and Colitis Foundation of America.